ORTINGLOBE - Ortin Global
Financial Performance
Revenue Growth by Segment
Not disclosed in available documents.
Geographic Revenue Split
Not disclosed in available documents.
Profitability Margins
Net loss for the half-year ended September 30, 2025, was INR 67.79 Lakhs, an increase of 17.81% compared to the INR 57.54 Lakhs loss in the previous year's corresponding period. However, the annual loss narrowed by 89.47% from INR 804.10 Lakhs in FY24 to INR 84.64 Lakhs in FY25.
EBITDA Margin
Operating profit before working capital changes was negative INR 70.49 Lakhs for the half-year ended September 30, 2025, indicating that core operations are currently not generating positive cash flow.
Capital Expenditure
Not disclosed in available documents.
Credit Rating & Borrowing
Non-current borrowings increased by 272% to INR 93.00 Lakhs as of September 30, 2025, from INR 25.00 Lakhs as of March 31, 2025. Finance costs for the half-year were INR 0.15 Lakhs.
Operational Drivers
Raw Materials
Not disclosed in available documents.
Import Sources
Not disclosed in available documents.
Key Suppliers
Not disclosed in available documents.
Capacity Expansion
Not disclosed in available documents.
Raw Material Costs
Not disclosed in available documents.
Manufacturing Efficiency
Operating profit before working capital changes was negative INR 70.49 Lakhs, indicating that current production levels or pricing are insufficient to cover operating costs.
Logistics & Distribution
Not disclosed in available documents.
Strategic Growth
Expected Growth Rate
Not disclosed in available documents.
Growth Strategy
The company is undergoing a strategic rebranding to 'Ortin Global Limited' to potentially expand its market reach. The Audit Committee is also mandated to review the rationale and cost-benefits of any mergers or demergers to drive future growth.
Products & Services
Pharmaceutical formulations and laboratory services (formerly Ortin Laboratories Limited).
Brand Portfolio
Not disclosed in available documents.
New Products/Services
Not disclosed in available documents.
Market Expansion
The name change to Ortin Global Limited suggests a plan to expand into international markets, though specific regions and timelines are not disclosed.
Market Share & Ranking
Not disclosed in available documents.
Strategic Alliances
Not disclosed in available documents.
External Factors
Industry Trends
The pharmaceutical industry is seeing a shift towards global integration. Ortin is positioning itself through a name change to 'Global' to align with these trends, despite current financial headwinds.
Competitive Landscape
Not disclosed in available documents.
Competitive Moat
Not disclosed in available documents.
Macro Economic Sensitivity
Not disclosed in available documents.
Consumer Behavior
Not disclosed in available documents.
Geopolitical Risks
Not disclosed in available documents.
Regulatory & Governance
Industry Regulations
Operations are subject to pharmaceutical manufacturing standards and SEBI/Companies Act regulations. Compliance is essential to avoid legal penalties that could strain the company's limited equity of INR 1.30 Cr.
Environmental Compliance
Not disclosed in available documents.
Taxation Policy Impact
Not disclosed in available documents.
Legal Contingencies
Not disclosed in available documents.
Risk Analysis
Key Uncertainties
The primary risk is the continued erosion of equity, with 'Other Equity' standing at negative INR 6.83 Cr, and the ability to service the 272% increase in borrowings.
Geographic Concentration Risk
Not disclosed in available documents.
Third Party Dependencies
Not disclosed in available documents.
Technology Obsolescence Risk
Not disclosed in available documents.
Credit & Counterparty Risk
Trade receivables decreased by INR 3.60 Lakhs, indicating a small but active collection cycle.